Pfiz­er tags ear­ly re­search pro­grams for 'ex­ter­nal­iza­tion' as it nar­rows fo­cus in rare dis­ease, can­cer

Pfiz­er is look­ing to di­vest a sig­nif­i­cant por­tion of its ear­ly-stage re­search pro­grams in rare dis­ease and on­col­o­gy as it re­thinks the way it ap­proach­es these big ar­eas, the com­pa­ny con­firmed to End­points News.

The fi­nan­cial news site Bar­ron’s first re­port­ed that Pfiz­er told em­ploy­ees it is pulling back on ear­ly re­search in­to cer­tain rare dis­eases, in­clud­ing work on gene ther­a­pies, as well as can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER